CompletedPhase 4

Protect and Improve Cluster of Differentiation 4 (CD4) Cells and B Cells Lymphocytes

United States, Vietnam60 participantsStarted 2015-12

Plain-language summary

This is a plant-based medication used to increase the amount, protect, and reduce HIV's impact on T and B lymphocytes.

Who can participate

Age range18 Years – 60 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Participants have a decline in CD4 + T-lymphocytes is the hallmark of HIV-1 infection. Characterized by rapid loss of resistance: AIDS * Dermatitis, mouth ulcers, skin rash, itching, weight loss * HCV (+), HBV (+), Tuberculosis (+) Exclusion Criteria: * Cancer under all form

What they're measuring

The CD4 cell count measurement

Timeframe: - 9 months

Trial details

NCT IDNCT04770701

SponsorTrieu, Nguyen Thi, M.D.

Sponsor typeINDIV

Study typeINTERVENTIONAL

Primary completion2021-01-08

View on ClinicalTrials.gov More HIV-1-infection trials